NCT06226350
A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma
An Open, Single-arm, Multicenter Phase II Trial of Efficacy and Safety of F520 Monotherapy in the Treatment of Advanced, Persistent, Recurrent, or Metastatic Cervical Cancer
Shandong New Time Pharmaceutical Co., LTD·Phase 2·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Cervical Cancer
- Drug/Device/Intervention
- Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Location
- Shandong, China
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Mar 04, 2021
- End date
- Jan 03, 2024
- Enrollment
- 29 participants
Primary outcome
Objective tumor response rate (ORR) assessed by RECIST1.1
Summary
This study was an open, single-arm, enriched, multicenter Phase II study.
ICD-10 classifications
Severe cervical dysplasia, not elsewhere classifiedMild cervical dysplasiaModerate cervical dysplasiaCarcinoma in situ: Cervix, unspecifiedCervical root disorders, not elsewhere classified
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06226350
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06226350 through Pure Global AI's free database. This Phase 2 trial is sponsored by Shandong New Time Pharmaceutical Co., LTD and is currently Completed. The study focuses on Cervical Cancer. Target enrollment is 29 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.